Q32 Bio Inc. (QTTB)
NASDAQ: QTTB · Real-Time Price · USD
4.240
+0.370 (9.56%)
At close: Feb 6, 2026, 4:00 PM EST
4.320
+0.080 (1.89%)
After-hours: Feb 6, 2026, 7:59 PM EST
Q32 Bio Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
26
Market Cap
52.17M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | -6.65M | -9.86M | - |
| Dec 31, 2022 | 3.21M | -30.76M | -90.56% |
| Dec 31, 2021 | 33.97M | 31.27M | 1,157.25% |
| Dec 31, 2020 | 2.70M | 1.04M | 62.18% |
| Dec 31, 2019 | 1.67M | -3.66M | -68.70% |
| Dec 31, 2018 | 5.32M | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Radiopharm Theranostics | 8.20M |
| CervoMed | 6.16M |
| Lipocine | 4.32M |
| Nutriband | 2.28M |
| Entera Bio | 124.00K |
| Impact BioMedical | 25.00K |
QTTB News
- 2 months ago - Dow Dips 200 Points; Q32 Bio Shares Jump - Benzinga
- 2 months ago - Why Is Small-Cap Q32 Bio Stock Soaring On Monday? - Benzinga
- 2 months ago - Q32 Bio Sells Complement Inhibitor ADX-097 - PRNewsWire
- 3 months ago - Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 3 months ago - Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata - PRNewsWire
- 5 months ago - Q32 Bio to Participate in the 2025 Wells Fargo Healthcare Conference - PRNewsWire
- 6 months ago - Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 8 months ago - Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer - PRNewsWire